CIK 0001601830
- Large accelerated filer
RECURSION PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- RXRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 464099738
- Phone
- +1 385-269-0203
- Business address
- 41S RIO GRANDE STREET, SALT LAKE CITY, UT, 84101
- Former names
- Recursion Pharmaceuticals, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $701,222
- in 5 filings, $701K under 10b5-1 plans
Net −$701,222. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Exercise or conversion · Stock Option (Right to Buy) | −31,250 | 375,000 | ||
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −10,000 | 6,481,496 | ||
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −4,000 | 515,000 | ||
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −20,000 | 408,000 | ||
| 2024-01-03 | Gibson Christopher Chief Executive Officer | Conversion · Class B Common Stock | −1,000 | 118,875 | ||
| 2024-01-02 | CHAVEZ R. MARTIN Director | Grant or award | +1,900 | 58,077 | ||
| 2024-01-02 | Dar Zavain Director | Grant or award | +1,393 | 55,216 | ||
| 2024-01-02 | Li Dean Y Director | Grant or award | +1,203 | 1,327,618 | ||
| 2023-12-28 | Larson Tina Marriott President and COO | Exercise or conversion 10b5-1 | +8,000 | $1.06 | $8K | 422,548 |
| 2023-12-28 | Larson Tina Marriott President and COO | Sale 10b5-1 | −8,000 | $10.58 | $85K | 414,548 |
| 2023-12-28 | Larson Tina Marriott President and COO | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −8,000 | 512,000 | ||
| 2023-12-26 | Borgeson Blake Director | Sale 10b5-1 | −20,054 | $10.63 | $213K | 7,364,472 |
| 2023-12-15 | Virani Shafique Chief Business Officer | Exercise or conversion 10b5-1 | +18,000 | $2.22 | $40K | 154,748 |
| 2023-12-15 | Virani Shafique Chief Business Officer | Sale 10b5-1 | −18,000 | $9.60 | $173K | 136,748 |
| 2023-12-15 | Virani Shafique Chief Business Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −18,000 | 379,469 | ||
| 2023-12-14 | Dar Zavain Director | Sale 10b5-1 | −20,141 | $9.00 | $181K | 53,823 |
| 2023-12-13 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 981,014 |
| 2023-12-13 | Secora Michael Chief Financial Officer | Sale 10b5-1 | −25,000 | $7.59 | $190K | 956,014 |
| 2023-12-13 | Secora Michael Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −37,500 | 1,110,135 | ||
| 2023-12-12 | Secora Michael Chief Financial Officer | Exercise or conversion 10b5-1 | +37,500 | $2.22 | $83K | 968,514 |
Page 27 of 41 · 805 trades